INmune Bio stock sits 37.69 percent below its 52-week high

Published on 10/20/2026 at 20:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

INmune Bio held USD 18.4 million cash on June 30, 2026. INmune Bio stock costs EUR 1.45 on October 20, 2026 at 8:14 p.m. CEST.

Price frame and cash

INmune Bio stock sits 37.69 percent below its USD 2.60 52-week high.
INmune Bio held USD 18.4 million in cash as of June 30, 2026.
INmune Bio stock costs EUR 1.45 at Lang & Schwarz on October 20, 2026 at 8:14 p.m. CEST.
Market capitalization stood at USD 45.1 million on October 20, 2026.

INMB, US45782T1051, Illustration mit AI erstellt.

INmune Bio (ISIN US45782T1051) stock sits 37.69 percent below its USD 2.60 52-week high, using a Nasdaq quote of USD 1.62 on October 20, 2026. The distance leaves the company valued against a small-cap biotechnology profile while regulatory milestones remain the central investor reference. Barron's identifies the listing as Nasdaq and reports the USD 2.60 yearly high.

At Lang & Schwarz, the stock was trading at EUR 1.45 on October 20, 2026 at 8:14 p.m. CEST. The euro quotation is the German investor reference, while the Nasdaq quote provides the original-currency view used for the 52-week comparison.

Cash extends the operating runway

INmune Bio held USD 18.4 million in cash and cash equivalents as of June 30, 2026. The company also received approximately USD 4.2 million from an Australian research and development tax rebate after the quarter, according to the Benzinga transcript of the October 12, 2026 earnings call.

The same transcript said existing resources were expected to fund operations into the second quarter of 2027. Management also described a monthly burn rate of USD 1.0 million to USD 1.5 million, making cash preservation a measurable part of the company story.

Regulatory milestones set the next dates

INmune Bio said it expected to submit the ABSTRACEL Marketing Authorization Application to the UK regulator by the end of the third quarter or early fourth quarter of 2026. The call also described planned European and U.S. submissions in early 2027, while FDA Fast Track status for XPro remains part of the development program, according to Benzinga.

How does the valuation compare?

INmune Bio had a market capitalization of USD 45.1 million on October 20, 2026. Keros Therapeutics (Nasdaq, USD) was up 4.07 percent with a market capitalization of USD 228.2 million, while Immunome (Nasdaq, USD) was up 8.41 percent at USD 2.1 billion. The comparison shows the much smaller scale of INmune Bio within this biotechnology group without turning the peer moves into a forecast.

Stock stays below its yearly high

The stock's USD 1.62 Nasdaq quotation on October 20, 2026 was 37.69 percent below the USD 2.60 high and above the USD 1.09 low reported for the same 52-week period. The current euro quote and the U.S. listing therefore describe separate venue and currency views rather than one combined daily change. The further course of trading is shown by the continuously updated real-time quote of INmune Bio stock.